GL1X · GenesisL1 explorer

MolNFT v1 · #14090 · protein

Analysis of quinazoline and pyridopyrimidine N9-C10 reversed bridge antifolates in complex with NADP+ and pneumocystis carinii dihydrofolate reductase

1LY3: “Analysis of quinazoline and pyridopyrimidine N9-C10 reversed bridge antifolates in complex with NADP+ and…”. X-ray diffraction, 2 ligands (NAP, COG), 1 pocket (best druggability 0.73). MolNFT v1 #14090 on GenesisL1: 3D structure…

PDB
1LY3
Type
protein
Length
206 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Dihydrofolate reductase
EC
1.5.1.3
UniProt
P16184
Ligands
NAP, COG
Pockets
1 · best druggability 0.73

Structure

x-ray diffraction · 1 distinct chain · 23% helix, 31% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ADihydrofolate reductase (EC 1.5.1.3)protein20623% helix, 31% strandP16184

Ligands and binding sites

  • NAP · Nadp nicotinamide-adenine-dinucleotide phosphate · ligand · chains A
  • COG · 2,4-diamino-6-[N-(2',5'-dimethoxybenzyl)-N-methylamino]quinazoline · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15080.730.8150NAP, COG

Compared structures

  • 1LY3 · Analysis of quinazoline and pyridopyrimidine N9-C10 reversed bridge antifolates in… · the same entry in another collection · chain A against A, TM-score 1.00
  • P16184 · AlphaFold monomer V2.0 prediction for dihydrofolate reductase (P16184) · a predicted model of the same protein · chain A against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.